Aileron Therapeutics Inc (ALRN)
NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price & Analysis

1,174 Followers

ALRN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.79 - $15.00
Previous Close$2.97
Volume4.17K
Average Volume (3M)32.59K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$25.48M
Total Debt (Recent Filing)$67.00K
Price to Earnings (P/E)-0.5
Beta-0.23
Next EarningsApr 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-6.52
Shares Outstanding4,541,179
R-Squared0.08
Standard Deviation0.37
10 Day Avg. Volume25,802
30 Day Avg. Volume32,595
Price to Book (P/B)0.61
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.04
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ALRN FAQ

What was Aileron Therapeutics’s price range in the past 12 months?
Aileron Therapeutics lowest stock price was $1.79 and its highest was $15.00 in the past 12 months.
    What is Aileron Therapeutics’s market cap?
    Currently, no data Available
    When is Aileron Therapeutics’s upcoming earnings report date?
    Aileron Therapeutics’s upcoming earnings report date is Apr 03, 2023 which is in 66 days.
      How were Aileron Therapeutics’s earnings last quarter?
      Aileron Therapeutics released its earnings results on Nov 01, 2022. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.65 by $0.25.
        Is Aileron Therapeutics overvalued?
        According to Wall Street analysts Aileron Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Aileron Therapeutics pay dividends?
          Aileron Therapeutics does not currently pay dividends.
          What is Aileron Therapeutics’s EPS estimate?
          Aileron Therapeutics’s EPS estimate is -$1.32.
            How many shares outstanding does Aileron Therapeutics have?
            Aileron Therapeutics has 4,541,180 shares outstanding.
              What happened to Aileron Therapeutics’s price movement after its last earnings report?
              Aileron Therapeutics reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.65. Following the earnings report the stock price went up 2.5%.
                Which hedge fund is a major shareholder of Aileron Therapeutics?
                Currently, no hedge funds are holding shares in ALRN

                ---

                Aileron Therapeutics Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -63.78%
                12-Months-Change

                Fundamentals

                Return on Equity
                -81.26%
                Trailing 12-Months
                Asset Growth
                -50.28%
                Trailing 12-Months
                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Aileron Therapeutics Inc

                Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Plus Therapeutics
                Biocept
                Organovo Holdings
                Sigilon Therapeutics
                GlobeStar Therapeutics

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis